Ro 09-0410: structure given in first source [MeSH]
| ID Source | ID |
|---|---|
| PubMed CID | 6438866 |
| CHEMBL ID | 3612748 |
| MeSH ID | M0110975 |
| Synonym |
|---|
| (2e)-1-(4-ethoxy-2-hydroxy-6-methoxyphenyl)-3-(4-methoxyphenyl)-2-propen-1-one |
| ro 09-0410 |
| (e)-1-(4-ethoxy-2-hydroxy-6-methoxy-phenyl)-3-(4-methoxyphenyl)prop-2-en-1-one |
| (e)-1-(4-ethoxy-2-hydroxy-6-methoxyphenyl)-3-(4-methoxyphenyl)prop-2-en-1-one |
| ro-09-0410 |
| 2-propen-1-one, 1-(4-ethoxy-2-hydroxy-6-methoxyphenyl)-3-(4-methoxyphenyl)- |
| 4'-ethoxy-2'-hydroxy-4,6'-dimethoxychalcone |
| 76554-66-0 |
| ro-09410 |
| CHEMBL3612748 |
| 4'-ethoxy-2'-hydroxy-4,6'-dimetho-xychalcone |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1244033 | Cytotoxicity against human HeLa cells | 2015 | European journal of medicinal chemistry, Aug-28, Volume: 101ISSN: 1768-3254 | Chalcone scaffolds as anti-infective agents: structural and molecular target perspectives. |
| AID1244032 | Antiviral activity against Rhinovirus infected in human HeLa cells | 2015 | European journal of medicinal chemistry, Aug-28, Volume: 101ISSN: 1768-3254 | Chalcone scaffolds as anti-infective agents: structural and molecular target perspectives. |
| AID1854351 | Antiviral activity against HRV infected in human HeLa cells assessed as inhibition in virus replication by plaque assay | 2022 | European journal of medicinal chemistry, Oct-05, Volume: 240ISSN: 1768-3254 | Chalcone-amide, a privileged backbone for the design and development of selective SARS-CoV/SARS-CoV-2 papain-like protease inhibitors. |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 11 (64.71) | 18.7374 |
| 1990's | 4 (23.53) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (5.88) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 4 (23.53%) | 5.53% |
| Reviews | 5 (29.41%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (47.06%) | 84.16% |
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| chalcone | chalcone | EC 3.2.1.1 (alpha-amylase) inhibitor | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| 4-hydroxychalcone | chalcones; phenols | antihypertensive agent; plant metabolite | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| 2',6'-dihydroxy-4'-methoxychalcone | chalcones | 2015 | 2015 | 9.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 | ||
| licochalcone a | chalcones | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | ||
| 2-chloro-4',6'-dimethoxy-2'-hydroxychalcone | 2015 | 2015 | 9.0 | high | 0 | 0 | 0 | 0 | 1 | 0 | |||
| GRL-0617 | benzamides; naphthalenes; secondary carboxamide; substituted aniline | anticoronaviral agent; protease inhibitor | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 | |
| 1-[(1R)-1-(1-ethylsulfonyl-4-piperidinyl)ethyl]-N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-3-indolecarboxamide | indolecarboxamide | 2022 | 2022 | 2.0 | medium | 0 | 0 | 0 | 0 | 0 | 1 |
| Condition | Indicated | Studies | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Catarrh | 0 | 1984 | 1987 | 38.5 | high | 3 | 4 | 0 | 0 | 0 | 0 | |
| Common Cold | 0 | 1984 | 1987 | 38.5 | high | 3 | 4 | 0 | 0 | 0 | 0 | |
| Hepatitis B | 0 | 1986 | 1986 | 38.0 | low | 1 | 1 | 0 | 0 | 0 | 0 | |
| Hepatitis B Virus Infection | 0 | 1986 | 1986 | 38.0 | low | 1 | 1 | 0 | 0 | 0 | 0 | |
| Infections, Picornaviridae | 0 | 1982 | 1985 | 40.5 | medium | 0 | 2 | 0 | 0 | 0 | 0 |